(Q50951718)

25 March 2018

title

Natalizumab and the development of extensive brain lesions in neuromyelitis optica. (English)

1 reference

25 March 2018

3

Krzysztof Selmaj

1 reference

25 March 2018

Maciej Juryńczyk

series ordinal

1

object named as

Maciej Juryńczyk

1 reference

25 March 2018

author name string

Krzysztof Zaleski

series ordinal

2

1 reference

25 March 2018

publication date

30 May 2013

1 reference

25 March 2018

published in

Journal of Neurology

1 reference

25 March 2018

volume

260

1 reference

25 March 2018

issue

7

1 reference

25 March 2018

page(s)

1919-1921

1 reference

25 March 2018

Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6965-4

Conventional brain MRI in neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6965-4

Does natalizumab therapy worsen neuromyelitis optica?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6965-4

Failure of natalizumab to prevent relapses in neuromyelitis optica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6965-4

Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6965-4

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6965-4

Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6965-4

Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6965-4

Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6965-4

Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6965-4

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-013-6965-4

Brain abnormalities in neuromyelitis optica

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23719787

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00415-013-6965-4

1 reference

25 March 2018

1 reference

25 March 2018